- Record: found
- Abstract: found
- Article: not found
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
Richard H Ko
1 ,
Lingyun Ji ,
Phillip Barnette ,
Bruce Bostrom ,
Raymond Hutchinson ,
Elizabeth Raetz ,
Nita L Seibel ,
Clare J Twist ,
Elena Eckroth ,
Richard Sposto ,
Paul S Gaynon ,
Mignon L Loh
Feb 01 2010
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Despite improvements in treatment, approximately 20% of patients with acute lymphoblastic leukemia (ALL) experience relapse and do poorly. The Therapeutic Advances in Childhood Leukemia (TACL) Consortium was assembled to assess novel drugs for children with resistant leukemia. We hypothesize that novel agents and combinations that fail to improve baseline complete remission rates in comparable populations are unlikely to contribute to better outcomes and should be abandoned. We sought to define response rates and disease-free survival (DFS) rates in patients treated at TACL institutions, which could serve as a comparator for future studies.